Akademik Veri Yönetim Sistemi
ECTRIMS, Vienna, Avusturya, 13 - 15 Kasım 2021, ss.278
Introduction: Ocrelizumab is the first drug approved for both relapsing and progressive MS. Aims: To characterize patients initiating ocrelizumab in a realworld setting and to evaluate early treatment response to ocrelizumab at the sixth month of treatment, using not only clinical parameters, but also with cognitive tests, in a single center clinic. Methods: The data of 304 pwMS (180 women) were investigated in this prospective study. Mean age was 49.65. Physical disability levels were assessed using the Expanded Disability Status Scale (EDSS), Nine Peg Hole test (NPHT), Timed 25-Foot Walk (T25FW). Cognitive performance was assessed using Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS- SDMT; Symbol Digit Modalities Test; CVLT-II; California Verbal Learning Test-II; BVMT-R; Brief Visuospatial Memory Test-Revised) compared to healthy controls. Each test was done twice; before ocrelizumab initation and at the sixth month. To evaluate effectiveness, we analysed 244 patients who had taken both first and second doses of ocrelizumab with Wilcoxon test. Results: The avarage disease duration was approximately 17.7 years and average EDSS score was 5.29. Participants’ clinical characteristics of the disease were 87 RRMS, 175 SPMS, and 42 were PPMS. There was no discontinuation due to a cause related to ocrelizumab at early stage. There was no significant difference between baseline and sixth month EDSS scores for RRMS, PPMS and SPMS patients (p:0,102, p:0,317 and 0,366, respectively). BVMT-R and CVLT-II scores were significantly increased at month 6 according to baseline (20.72±8.11 vs. 22.73±7.48, 46.50±12.99 vs. 49.91±12.78, respectively) (p< 0.05). No significant difference observed between the baseline and month 6 in term of SDMT (34.37±14.95 vs. 34.51±15.67), T25FW (12.95±10.30 vs. 16.28±14.75), and 9-DPT (35.45±22.35 vs. 35.34±20.23) scores (p>0.05). Conclusions: Between baseline and sixth-month assessments, there was no significant progression in physical disability scores, and increased cognitive performance based on visiospatial skills and verbal memory. Disclosure Nothing to disclose